Truvestments Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.25M | Buy |
44,503
+620
| +1% | +$16.5K | 0.23% | 120 |
|
|
2025
Q4 | $1.09M | Sell |
43,883
-3,255
| -7% | -$82.1K | 0.2% | 118 |
|
|
2025
Q3 | $1.2M | Buy |
47,138
+30,077
| +176% | +$742K | 0.22% | 103 |
|
|
2025
Q2 | $414K | Buy |
17,061
+281
| +2% | +$6.55K | 0.08% | 175 |
|
|
2025
Q1 | $425K | Buy |
16,780
+1,751
| +12% | +$45.8K | 0.09% | 161 |
|
|
2024
Q4 | $399K | Buy |
15,029
+90
| +0.6% | +$2.44K | 0.1% | 152 |
|
|
2024
Q3 | $432K | Buy |
14,939
+1,985
| +15% | +$57.9K | 0.12% | 141 |
|
|
2024
Q2 | $362K | Sell |
12,954
-58
| -0.4% | -$1.6K | 0.14% | 146 |
|
|
2024
Q1 | $361K | Sell |
13,012
-253
| -2% | -$7.02K | 0.14% | 147 |
|
|
2023
Q4 | $382K | Sell |
13,265
-529
| -4% | -$16K | 0.17% | 120 |
|
|
2023
Q3 | $458K | Buy |
13,794
+9
| +0.1% | +$318 | 0.24% | 77 |
|
|
2023
Q2 | $506K | Buy |
13,785
+12
| +0.1% | +$467 | 0.25% | 78 |
|
|
2023
Q1 | $562K | Sell |
13,773
-384
| -3% | -$16.6K | 0.3% | 66 |
|
|
2022
Q4 | $725K | Buy |
14,157
+27
| +0.2% | +$1.29K | 0.41% | 64 |
|
|
2022
Q3 | $618K | Buy |
14,130
+12
| +0.1% | +$583 | 0.39% | 61 |
|
|
2022
Q2 | $740K | Buy |
14,118
+311
| +2% | +$15.8K | 0.43% | 59 |
|
|
2022
Q1 | $715K | Buy |
13,807
+91
| +0.7% | +$4.72K | 0.39% | 65 |
|
|
2021
Q4 | $810K | Sell |
13,716
-794
| -5% | -$39.3K | 0.41% | 65 |
|
|
2021
Q3 | $624K | Buy |
14,510
+63
| +0.4% | +$2.79K | 0.34% | 72 |
|
|
2021
Q2 | $566K | Sell |
14,447
-18,138
| -56% | -$705K | 0.31% | 81 |
|
|
2021
Q1 | $1.18M | Buy |
32,585
+11,127
| +52% | +$395K | 0.67% | 51 |
|
|
2020
Q4 | $790K | Buy |
21,458
+1,371
| +7% | +$50.3K | 0.55% | 59 |
|
|
2020
Q3 | $699K | Sell |
20,087
-2,139
| -10% | -$75K | 0.63% | 56 |
|
|
2020
Q2 | $688K | Buy |
22,226
+1,229
| +6% | +$41.8K | 0.7% | 43 |
|
|
2020
Q1 | $650K | Sell |
20,997
-13,203
| -39% | -$450K | 0.83% | 37 |
|
|
2019
Q4 | $1.27M | Sell |
34,200
-860
| -2% | -$30.6K | 0.88% | 38 |
|
|
2019
Q3 | $1.2M | Sell |
35,060
-1,514
| -4% | -$55.1K | 0.78% | 38 |
|
|
2019
Q2 | $1.5M | Sell |
36,574
-1,847
| -5% | -$73.3K | 1.01% | 29 |
|
|
2019
Q1 | $1.55M | Buy |
+38,421
| New | +$1.54M | 1.19% | 20 |
|
|
2018
Q3 | $2.23M | Buy |
53,248
+20,160
| +61% | +$776K | 1.07% | 18 |
|
|
2018
Q2 | $1.14M | Buy |
+33,088
| New | +$1.13M | 0.72% | 42 |
|
Other funds holding PFE
VCM
VPM
Truvestments Capital's PFE Position: Q1 2026 in Review
Truvestments Capital increased its Pfizer (PFE) stake by 1.4% in Q1 2026, buying an estimated $16.5K and bringing the position to 44,503 shares worth $1.25M. The position accounts for 0.23% of the portfolio, ranked #120.
Truvestments Capital first reported a position in PFE in Q2 2018 and has held it in 31 quarters since. The position peaked at $2.23M in Q3 2018. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Truvestments Capital held 44,503 shares of Pfizer worth $1.25M as of Q1 2026.
- Truvestments Capital bought 620 Pfizer shares in Q1 2026, an estimated $16.5K.
- Pfizer made up 0.23% of Truvestments Capital's portfolio in Q1 2026, its #120 holding.
- Truvestments Capital first reported a position in Pfizer in Q2 2018 and has held it in 31 quarters since.
- Truvestments Capital's Pfizer position peaked at $2.23M in Q3 2018.
- 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.